Table 5.
Baseline characteristics of idiopathic pulmonary fibrosis patients who were diagnosed since 2016 according to treatment
| No treatment (n=33) | Antifibrotics (n=420) | Non-antifibrotics (n=77) | p-value | |
|---|---|---|---|---|
| Age | 73.4±6.6 | 70.8±8.0 | 69.6±9.1 | 0.073 |
| Sex (male:female) | 28:5 | 350:70 | 62:15 | 0.799 |
| FVC (L) | 3.19±0.82 | 2.83±0.74* | 2.78±0.91* | 0.028 |
| FVC % predicted | 83.9±17.4 | 73.0±13.7* | 73.1±20.8* | <0.001 |
| FEV1 (L) | 2.37±0.58 | 2.23±0.52 | 2.16±0.65 | 0.199 |
| FEV1 %predicted | 91.9±81.0 | 83.8±14.8* | 81.0±22.0* | 0.006 |
| DLco (mL/mm Hg/min) | 12.50±5.18 | 11.21±4.97 | 11.54±4.47 | 0.341 |
| DLco % predicted | 70.6±24.6 | 59.3±18.1* | 60.5±21.8* | 0.006 |
Values are presented as mean±SD.
*
p<0.05 compared to the no treatment group.
FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; DLco: diffusing capacity for carbon monoxide; SD: standard deviation.